NMTR News and Press, 9 Meters Biopharma Inc. From 12/21/20

uniQure (QURE) -18% after the FDA clinical hold on its hemophilia B gene therapy program, including the pivotal, Phase 3 HOPE-B study.MingZhu Logistics Holdings Limited (YGMZ) -11%.CYREN (CYRN) -13%.Transocean (RIG) -11%.The9 (NCTY) -11%.DBV Technologies (DBVT) -11%.FibroG...

Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-19 patients EBRIS will advance larazotide into an Australian Investigational New Drug...

Can These 5 Penny Stocks Continue to Rally? Throughout the month of December, investors have seen a lot of positive sentiment with penny stocks . While trading these stocks has changed in 2020, the majority of the factors remain largely the same. This includes understanding the fund...

RALEIGH, NC / ACCESSWIRE / December 15, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the closing of its previously announced underwritten public offering of 53,076,924 shares of its comm...

9 Meters Biopharma (NMTR) slumped 18.2% premarket on pricing public offering of ~46.15M common shares at $0.65/share, for gross proceeds of ~$30M.Underwriters' over-allotment is an additional 6,923,077 shares.Offering is expected to close on December 15. Net proceeds together with o...

RALEIGH, NC / ACCESSWIRE / December 11, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the pricing of an underwritten public offering of 46,153,847 shares of its common stock at a price to...

9 Meters Biopharma (NMTR) has commenced a proposed public offering of common shares.Actual size, price or terms are not yet determined.Underwriters' over-allotment is an additional 15% of shares. Net proceeds will be used for the clinical development of product candidates, for working capital...

RALEIGH, NC / ACCESSWIRE / December 10, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this ...

aGvHD among potential indications being considered for next stage of development Candidate to move to IND-enabling studies in 2021 RALEIGH, NC / ACCESSWIRE / December 9, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology co...

-Rapid onset and sustained clinical effect following first dose in all 9 patients in total stool output (TSO) volume -Clinically relevant improvements in TSO volume and bowel movement frequency -Twice-monthly fixed-dosing regimen exhibited an excellent safety and tolerability profile -Plan t...